Regeneron’s second quarter was marked by strong commercial execution and robust product demand, resulting in financial results that surpassed Wall Street’s expectations and a significant positive market reaction. Management attributed this performance to continued momentum for key products, such as Dupixent, EYLEA HD, and Libtayo, each reaching new sales highs. CEO Leonard Schleifer highlighted that Dupixent’s broad adoption across multiple indications and EYLEA HD’s growing physician uptake, especially after recent label expansions, were central to the company’s revenue growth. Schleifer also pointed to Libtayo’s expanded use in oncology as another meaningful contributor this quarter.
Is now the time to buy REGN? Find out in our full research report (it’s free for active Edge members).
Regeneron (REGN) Q2 CY2026 Highlights:
- Revenue: $4.29 billion vs analyst estimates of $3.82 billion (16.7% year-on-year growth, 12.4% beat)
- Adjusted EPS: $14.29 vs analyst estimates of $10.20 (40.1% beat)
- Operating Margin: 30.1%, in line with the same quarter last year
- Market Capitalization: $76.75 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Regeneron’s Q2 Earnings Call
-
Christopher Raymond (Raymond James) asked about Regeneron’s large cash balance and approach to mergers and acquisitions. CEO Leonard Schleifer replied that the company is not averse to M&A but remains disciplined, seeking value-accretive deals that fit Regeneron’s long-term strategy.
-
Taylor Hanley (JPMorgan) questioned the status of the EYLEA HD prefilled syringe review and manufacturing readiness. Schleifer stated that multiple contract manufacturers are involved to ensure supply, and management remains optimistic about approval by year-end.
-
Mario Joshua Chazaro Cortes (Evercore ISI) inquired about the commercial strategy for cemdisiran in myasthenia gravis. EVP Marion McCourt emphasized differentiated clinical and safety profiles, with detailed launch strategies to be shared closer to approval.
-
Salveen Richter (Goldman Sachs) asked about the differentiation of Regeneron’s siRNA for MASH compared to existing therapies. CSO George Yancopoulos explained that their approach targets the genetic mechanism of the disease, aiming for deeper and more direct efficacy.
-
Tazeen Ahmad (Bank of America) probed the competitive outlook for cemdisiran in a crowded gMG market. McCourt and Schleifer highlighted the convenience of dosing and consistent efficacy as key differentiators, with Schleifer noting the potential to change clinical practice.
Catalysts in Upcoming Quarters
In the coming quarters, the StockStory team will be monitoring (1) regulatory decisions for cemdisiran and garetosmab, which could expand Regeneron’s rare disease portfolio; (2) the commercial uptake and prescriber adoption of EYLEA HD, especially following the anticipated prefilled syringe launch; and (3) progress on key pipeline programs in obesity, oncology, and complement-mediated diseases. Additional attention will be paid to competitive dynamics in retinal and immunology markets as biosimilars and new entrants emerge.
Regeneron currently trades at $770.13, up from $695.42 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).
The Best Stocks for High-Quality Investors
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.